Teladoc Health (TDOC) to Release Earnings on Wednesday

Teladoc Health (NYSE:TDOC - Get Free Report) is projected to post its Q1 2025 quarterly earnings results after the market closes on Wednesday, April 30th. Analysts expect the company to announce earnings of ($0.32) per share and revenue of $619.38 million for the quarter. Teladoc Health has set its Q1 2025 guidance at -0.400--0.150 EPS and its FY 2025 guidance at -1.100--0.500 EPS.

Teladoc Health (NYSE:TDOC - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The health services provider reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.07). Teladoc Health had a negative net margin of 37.91% and a negative return on equity of 10.06%. The company had revenue of $640.49 million during the quarter, compared to analysts' expectations of $639.44 million. On average, analysts expect Teladoc Health to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Teladoc Health Price Performance

TDOC stock traded up $0.40 during trading on Tuesday, hitting $6.91. The stock had a trading volume of 6,923,827 shares, compared to its average volume of 6,257,998. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -1.20 and a beta of 1.73. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.69 and a current ratio of 1.73. The company's 50 day moving average price is $8.92 and its two-hundred day moving average price is $9.60. Teladoc Health has a 1-year low of $6.35 and a 1-year high of $15.21.

Insider Activity at Teladoc Health

In other news, insider Adam C. Vandervoort sold 11,011 shares of the stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $8.42, for a total value of $92,712.62. Following the completion of the sale, the insider now owns 64,308 shares in the company, valued at approximately $541,473.36. This trade represents a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.95% of the company's stock.

Wall Street Analyst Weigh In

TDOC has been the topic of several recent analyst reports. Royal Bank of Canada upped their price objective on shares of Teladoc Health from $11.00 to $12.00 and gave the company an "outperform" rating in a research note on Friday, January 24th. Jefferies Financial Group reduced their price target on Teladoc Health from $10.00 to $8.00 and set a "hold" rating on the stock in a research note on Monday. Oppenheimer lowered their price objective on Teladoc Health from $14.00 to $12.00 and set an "outperform" rating for the company in a research report on Friday, January 24th. Needham & Company LLC reiterated a "hold" rating on shares of Teladoc Health in a research report on Thursday, February 27th. Finally, The Goldman Sachs Group decreased their price target on Teladoc Health from $16.00 to $13.00 and set a "buy" rating on the stock in a research note on Monday, March 3rd. Eleven equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $10.82.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.